[
    [
        {
            "time": "2021-06-30",
            "original_text": "健帆生物：公司现金理财产品已全部赎回",
            "features": {
                "keywords": [
                    "健帆生物",
                    "现金理财",
                    "赎回"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "健帆生物：公司现金理财产品已全部赎回",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-06-30",
            "original_text": "健帆生物：公司委托理财产品列报至“交易性金融资产”科目",
            "features": {
                "keywords": [
                    "健帆生物",
                    "委托理财",
                    "交易性金融资产"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "健帆生物：公司委托理财产品列报至“交易性金融资产”科目",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 2,
                "Time_Proximity": 6,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-06-30",
            "original_text": "健帆生物：限售股主要是高管锁定股及股权激励限售股",
            "features": {
                "keywords": [
                    "健帆生物",
                    "限售股",
                    "高管锁定股",
                    "股权激励"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "健帆生物：限售股主要是高管锁定股及股权激励限售股",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-06-30",
            "original_text": "健帆生物：上半年营业成本增加主要系本期产品销量增加所致",
            "features": {
                "keywords": [
                    "健帆生物",
                    "营业成本",
                    "产品销量",
                    "增加"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物：上半年营业成本增加主要系本期产品销量增加所致",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-06-30",
            "original_text": "健帆生物：公司不存在控股股东资金占用、非经营性资金占用及其他关联资金往来的情况",
            "features": {
                "keywords": [
                    "健帆生物",
                    "控股股东",
                    "资金占用",
                    "非经营性资金"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "健帆生物：公司不存在控股股东资金占用、非经营性资金占用及其他关联资金往来的情况",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-06-30",
            "original_text": "健帆生物：公司2021年上半年的营业成本为1.75亿元，相比去年同期增加0.5亿元，主要系本期产品销量增加所致",
            "features": {
                "keywords": [
                    "健帆生物",
                    "营业成本",
                    "产品销量",
                    "增加",
                    "同比"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "生物医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "健帆生物：公司2021年上半年的营业成本为1.75亿元，相比去年同期增加0.5亿元，主要系本期产品销量增加所致",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]